产品描述信息
NR-18378??Mycobacterium tuberculosis, CDC1551, Transposon Mutant 2137 (MT0433, Rv0419)(Mutant Bacteria)|Mycobacterium tuberculosis|CDC1551, Transposon Mutant 2137 (MT0433, Rv0419)|2°C to 8°C|WR Bishai and NIH - TB Vaccine Testing and Research Materials ContractAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Mycobacterium tuberculosis, Strain CDC1551, Transposon Mutant 2137 (MT0433, Rv0419), NR-18378.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. In 2002,
TARGET (Tuberculosis Animal Research and Gene Evaluation Taskforce) was formed to enable the modeling of human tuberculosis in multiple animal species using defined protocols and testing defined mutants of
Mycobacterium tuberculosis (M. tuberculosis). In addition to animal modeling activities, a library of intragenic transposon mutants has been created and characterized.
M. tuberculosis, transposon mutant 2137 was created by disruption of a possible lipoprotein peptidase (MT0433, Rv0419) of the wild-type strain CDC1551.Each tube contains a Lowenstein-Jensen (LJ) agar slant that was inoculated with 0.1 mL of bacterial culture and incubated 2 to 6 weeks at 37°C.TARGET:
MT0433Tuberculist:
Rv0419ORF Description: Lipoprotein peptidase ORF Size: 1497POI: 636Additional information is available at
Mycobacterium tuberculosis CDC1551 Transposon Mutant Library.This mutant was developed by Lamichhane, et al. at the Center for Tuberculosis Research, The Johns Hopkins University School of Medicine, PubMed:
12775759.